Virpax Pharmaceuticals, Inc. VRPX
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.29M | 781.00K | 1.50M | 1.69M | 3.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.39M | 1.92M | 3.46M | 3.30M | 4.68M |
| Operating Income | -3.39M | -1.92M | -3.46M | -3.30M | -4.68M |
| Income Before Tax | -3.39M | -2.01M | -3.45M | -3.22M | -4.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.39M | -2.01M | -3.45M | -3.22M | -4.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.39M | -2.01M | -3.45M | -3.22M | -4.56M |
| EBIT | -3.39M | -1.92M | -3.46M | -3.30M | -4.68M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -9.18 | -10.77 | -43.63 | -68.74 | -97.37 |
| Normalized Basic EPS | -5.74 | -6.73 | -27.27 | -42.96 | -60.86 |
| EPS Diluted | -9.18 | -10.77 | -43.63 | -68.74 | -97.37 |
| Normalized Diluted EPS | -5.74 | -6.73 | -27.27 | -42.96 | -60.86 |
| Average Basic Shares Outstanding | 369.40K | 186.30K | 79.10K | 46.80K | 46.80K |
| Average Diluted Shares Outstanding | 369.40K | 186.30K | 79.10K | 46.80K | 46.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |